AI summary · may contain errors
In women with breast cancer receiving moderately or highly emetogenic chemotherapy, adding olanzapine or prochlorperazine in Cycle 2 reduced persistent nausea versus placebo, with olanzapine improving maximum nausea by -0.59 (P=.02).
